(continued)
- Nereus: FDA Approves New Pill to Help With Motion Sickness
- FDA Approves Yartemlea, the First and Only Treatment for Transplant-Related Blood Vessel Damage
- Aqvesme: FDA Approves First Pill for Treating Anemia in Adults With Alpha- or Beta- Thalassemia
- Accrufer: FDA Expands Use of Oral Iron Treatment for Kids Ages 10 and Older
- Lunsumio Velo: FDA Approves a Convenient Under-the-Skin Shot for Relapsed or Refractory Follicular Lymphoma
- FDA Approves Once-Daily Wegovy Pill as the First Oral GLP-1 Medicine for Weight Loss in Adults With Obesity or Overweight
- FDA Expands Jascayd Approval to Adults With Progressive Pulmonary Fibrosis
- Fesilty: FDA Approves New Treatment Option for Rare Bleeding Disorder
- FDA Approves Myqorzo, a New Oral Therapy for Obstructive Hypertrophic Cardiomyopathy
- Exdensur: FDA Approves New Twice-Yearly Medicine for Severe Asthma
- FDA Approves Rybrevant Faspro: An Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer
- FDA Approves Lerochol: A Monthly Injectable Treatment to Reduce High LDL Cholesterol Levels in Adults
- Addyi: FDA Approves New Treatment for Low Sexual Desire in Postmenopausal Women
- Enhertu Plus Pertuzumab: New First-Line Option for Advanced HER2-Positive Metastatic Breast Cancer
- FDA Approves Akeega for Metastatic Prostate Cancer
- Cardamyst: FDA Approves Nasal Spray for Sudden Fast Heartbeats
- FDA Approves Nuzolvence for Drug-Resistant Gonorrhea
- FDA Approves Blujepa: First New Oral Antibiotic for Gonorrhea in Decades
- FDA Approves Uplizna: A Twice-Yearly Targeted Therapy for Adults With Generalized Myasthenia Gravis
- FDA Approves Breyanzi: First and Only CAR T-Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma
- Imfinzi: FDA Approves New Treatment Option for Early, Resectable, and Locally Advanced Gastric and Gastroesophageal Junction Cancers
- Voyxact: FDA Grants Accelerated Approval to Once-Monthly Injection for Adults With IgA Nephropathy
- Itvisma: FDA Approves One-Time Gene Therapy for Spinal Muscular Atrophy in Children 2 or Older, Teens, and Adults
- Hyrnuo: New Oral Treatment for Advanced HER2-Mutant Lung Cancer
- Keytruda and Padcev: FDA Approves New Combination Therapy for Aggressive Bladder Cancer
- Eylea HD: New Option for Treating Vision Loss from Macular Edema Caused by Retinal Vein Occlusion
- Koselugo: FDA Approves Second Oral Treatment for Adults With Neurofibromatosis Type 1
- Imdelltra Receives Full FDA Approval as First-In-Class Immunotherapy for Advanced Small-Cell Lung Cancer
- Epkinly: FDA Approves New Bispecific Antibody Option for Relapsed or Refractory Follicular Lymphoma
- Kygevvi: FDA Approves First Oral Treatment for Thymidine Kinase 2 Deficiency (TK2d)